PMID- 20118910
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 23
IP  - 4
DP  - 2010 Apr
TI  - Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy 
      cohort.
PG  - 539-46
LID - 10.1038/modpathol.2009.193 [doi]
AB  - The majority of prostate cancers harbor recurrent gene fusions between the 
      hormone-regulated TMPRSS2 and members of the ETS family of transcription factors, 
      most commonly ERG. Prostate cancer with ERG rearrangements represent a distinct 
      sub-class of tumor based on studies reporting associations with histomorphologic 
      features, characteristic somatic copy number alterations, and gene expression 
      signatures. This study describes the frequency of ERG rearrangement prostate 
      cancer and three 5 prime (5') gene fusion partners (ie, TMPRSS2, SLC45A3, and 
      NDRG1) in a large prostatectomy cohort. ERG gene rearrangements and mechanism of 
      rearrangement, as well as rearrangements of TMPRSS2, SLC45A3, and NDRG1, were 
      assessed using fluorescence in situ hybridization (FISH) on prostate cancer 
      samples from 614 patients treated using radical prostatectomy. ERG rearrangement 
      occurred in 53% of the 540 assessable cases. TMPRSS2 and SLC45A3 were the only 5' 
      partner in 78% and 6% of these ERG rearranged cases, respectively. Interestingly, 
      11% of the ERG rearranged cases showed concurrent TMPRSS2 and SLC45A3 
      rearrangements. TMPRSS2 or SLC45A3 rearrangements could not be identified for 5% 
      of the ERG rearranged cases. From these remaining cases we identified one case 
      with NDRG1 rearrangement. We did not observe any associations with pathologic 
      parameters or clinical outcome. This is the first study to describe the frequency 
      of SLC45A3-ERG fusions in a large clinical cohort. Most studies have assumed that 
      all ERG rearranged prostate cancers harbor TMPRSS2-ERG fusions. This is also the 
      first study to report concurrent TMPRSS2 and SLC45A3 rearrangements in the same 
      tumor focus, suggesting additional complexity that had not been previously 
      appreciated. This study has important clinical implications for the development 
      of diagnostic assays to detect ETS rearranged prostate cancer. Incorporation of 
      these less common ERG rearranged prostate cancer fusion assays could further 
      increase the sensitivity of the current PCR-based approaches.
FAU - Esgueva, Raquel
AU  - Esgueva R
AD  - Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 
      New York, NY, USA.
FAU - Perner, Sven
AU  - Perner S
FAU - J LaFargue, Christopher
AU  - J LaFargue C
FAU - Scheble, Veit
AU  - Scheble V
FAU - Stephan, Carsten
AU  - Stephan C
FAU - Lein, Michael
AU  - Lein M
FAU - Fritzsche, Florian R
AU  - Fritzsche FR
FAU - Dietel, Manfred
AU  - Dietel M
FAU - Kristiansen, Glen
AU  - Kristiansen G
FAU - Rubin, Mark A
AU  - Rubin MA
LA  - eng
GR  - R01 CA125612/CA/NCI NIH HHS/United States
GR  - R01 CA125612-03/CA/NCI NIH HHS/United States
GR  - CA125612/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100129
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Prevalence
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*genetics/surgery
MH  - Tissue Array Analysis
MH  - Trans-Activators/*genetics
MH  - Transcriptional Regulator ERG
PMC - PMC2848699
MID - NIHMS165730
EDAT- 2010/02/02 06:00
MHDA- 2010/06/16 06:00
PMCR- 2010/10/01
CRDT- 2010/02/02 06:00
PHST- 2010/02/02 06:00 [entrez]
PHST- 2010/02/02 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
PHST- 2010/10/01 00:00 [pmc-release]
AID - S0893-3952(22)02733-8 [pii]
AID - 10.1038/modpathol.2009.193 [doi]
PST - ppublish
SO  - Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 
      29.